Akorn files 28 ophthalmic ANDAs in 2016

Ophthalmics make up a significant fraction of products for which Akorn has filed abbreviated new drug applications with the FDA.In a presentation at the 35th annual J.P. Morgan Health Care Conference in San Francisco, Duane A. Portwood, chief financial officer of Akorn, said ophthalmics accounted for 28 of the company’s 92 ANDAs awaiting approval as of the end of 2016. Injectables also comprised a significant share of applications, he said, with 38 having been filed.